GlaxoSmithKline Pharmaceuticals on Friday said its net profit increased over five-fold to Rs 229 crore for the third quarter ended December 31, 2024.

India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday, led by sustained demand for its respiratory drugs and antibiotic Augmentin.

With Chinese firms becoming major players in drug development, the traditional balance of power in global pharmaceuticals is ...

After calling Rockville, Maryland, home for more than eight years, GSK's vaccine and infectious disease R&D teams are ...

Drug developer GSK is vacating its 635,000-square-foot life sciences lab in Rockville, Maryland, where it was the sole tenant ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

Arizona is suing a major drug maker, accusing it of gaming the system by simply renaming an asthma drug to allow it to ...

Last week’s full-year results from GlaxoSmithKline (GSK) do not answer every concern the sceptics may have regarding current ...

When drug companies manipulate the system to increase profits, patients suffer. Arizona Attorney General Kris Mayes is right to take GlaxoSmithKline to court over its decision to discontinue Flovent, ...

The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...

PHOENIX — Arizona is suing a major drug maker, accusing it of gaming the system by simply renaming an asthma drug to allow it ...

The lawsuit filed in Maricopa County Superior Court contends GlaxoSmithKline's actions violate the Arizona Consumer Fraud Act ...